Login
$NERV
$2.21 -$0.09 (3.91%) Live

$NERV SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 10-Q
06 Nov 2026 8-K: Results of Operations and Financial Condition

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027

03 Nov 2026 Form 4: Kaul Inderjit, Director

Granted 2,328 Stock Option (right to buy)

27 Oct 2026 SCHEDULE 13G
20 Aug 2026 Form 3: Reilly Joseph H., Chief Operating Officer

Holds 20,872 shares of Common Stock

20 Aug 2026 Form 3: Aliquo Anthony, Chief Accounting Officer

Holds 1,683 shares of Common Stock

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 Aug 2026 10-Q
07 Aug 2026 8-K: Results of Operations and Financial Condition

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027

03 Aug 2026 Form 4: Kaul Inderjit, Director

Granted 12,147 Stock Option (right to buy)

08 Jul 2026 SCHEDULE 13G/A
05 Jun 2026 Form 4: Ahlholm Frederick W, SVP, CFO and Secretary

Granted 680,000 Employee Stock Option (right to buy)

05 Jun 2026 Form 4: Luthringer Remy, Director

Granted 1,690,700 Employee Stock Option (right to buy)

05 Jun 2026 Form 4: Laghrissi-Thode Fouzia, Director

Granted 50,000 Stock Option (right to buy)

05 Jun 2026 Form 4: Kupfer David, Director

Granted 50,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support